<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303640</url>
  </required_header>
  <id_info>
    <org_study_id>C494</org_study_id>
    <nct_id>NCT01303640</nct_id>
  </id_info>
  <brief_title>NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial</brief_title>
  <acronym>NEXT</acronym>
  <official_title>NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeshi Morimoto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the newly-approved biolimus-eluting stent is
      not inferior to the everolimus-eluting stent in terms of the rate of target-lesion
      revascularization at 1-year and death or myocardial infarction at 3-year after stent
      implantation in the real world clinical practice.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Everolimus-eluting stent is the most widely used coronary drug-eluting stent in Japan.
      Biolimus-eluting stent is a new coronary drug-eluting stent, which is going to be approved in
      2011 by the Japanese Ministry of Health, Labor and Welfare. It has been reported that
      biolimus-eluting stent had lower rate of target-lesion revascularization and stent thrombosis
      at 9 months as compared with paclitaxel-eluting stent. However, trial results comparing
      biolimus-eluting stent with everolimus-eluting stent are largely unknown. The purpose of this
      study is to evaluate whether the newly-approved biolimus-eluting stent is not inferior to the
      everolimus-eluting stent in terms of the rate of target-lesion revascularization at 1-year
      and death or myocardial infarction at 3-year after stent implantation in the real world
      clinical practice. The design of this study is all-comer design enrolling patients scheduled
      for percutaneous coronary intervention using drug-eluting stents without any exclusion
      criteria.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target-lesion revascularization</measure>
    <time_frame>1-year</time_frame>
    <description>target-lesion revascularization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>death or myocardial infarction at 3-year after stent implantation</measure>
    <time_frame>3-year</time_frame>
    <description>death or myocardial infarction at 3-year after stent implantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>3-year</time_frame>
    <description>death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>3-year</time_frame>
    <description>death due to cardiac origins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute myocardial infarction</measure>
    <time_frame>3-year</time_frame>
    <description>acute myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>3-year</time_frame>
    <description>stent thrombosis defined by Academic Reseach Consortium definition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stroke</measure>
    <time_frame>3-year</time_frame>
    <description>stroke excluding transient ischemic attacks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding complications</measure>
    <time_frame>3-year</time_frame>
    <description>bleeding complications defined by GUSTO and TIMI definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>success rate for stent deployment</measure>
    <time_frame>3-year</time_frame>
    <description>success rate for stent deployment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedure time</measure>
    <time_frame>3-year</time_frame>
    <description>procedure time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>clinically-driven target-lesion revascularization</measure>
    <time_frame>3-year</time_frame>
    <description>clinically-driven target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-target-lesion revascularization</measure>
    <time_frame>3-year</time_frame>
    <description>non-target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coronary artery bypass grafting</measure>
    <time_frame>3-year</time_frame>
    <description>coronary artery bypass grafting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>target-vessel revascularization</measure>
    <time_frame>3-year</time_frame>
    <description>target-vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>any repeat coronary revascularization</measure>
    <time_frame>3-year</time_frame>
    <description>any repeat coronary revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of cardiac death, acute myocardial infarction in the territory of the target vessel or target-lesion revascularization</measure>
    <time_frame>3-year</time_frame>
    <description>composite of cardiac death, acute myocardial infarction in the territory of the target vessel or target-lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>composite of all-cause death, acute myocardial infarction or any repeat coronary revascularization</measure>
    <time_frame>3-year</time_frame>
    <description>composite of all-cause death, acute myocardial infarction or any repeat coronary revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3235</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Biolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Biolimus-eluting stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Everolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biolimus-eluting stent</intervention_name>
    <description>Biolimus-eluting stent</description>
    <arm_group_label>Biolimus-eluting stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Everolimus-eluting stent</intervention_name>
    <description>Everolimus-eluting stent</description>
    <arm_group_label>Everolimus-eluting stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for percutaneous coronary intervention using drug-eluting stents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takeshi Kimura, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Takeshi Morimoto</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

